GSK To Acquire RAPT Therapeutics in $2.2 Billion Deal

GSK Acquires Affinivax, Inc.

August 16, 2022

Biotechnology

GSK plc acquired clinical-stage biopharmaceutical company Affinivax, Inc., paying $2.1 billion upfront and up to $1.2 billion in potential development milestones to gain the MAPS vaccine platform and a 24‑valent pneumococcal vaccine candidate (AFX3772) in development. The acquisition (100% of outstanding shares) expands GSK's vaccines R&D capabilities and pipeline, with AFX3772 in phase II and preparations underway for phase III.

GSK to Acquire Aiolos Bio

January 9, 2024

Pharmaceuticals

GSK plc has entered an agreement to acquire Aiolos Bio, a clinical-stage biopharmaceutical company focused on unmet needs in respiratory and inflammatory conditions, for a $1 billion upfront payment and up to $400 million in success-based regulatory milestone payments. The deal gives GSK access to Aiolos’ AIO-001, a long-acting anti-TSLP monoclonal antibody (phase II-ready) intended for adult asthma and potentially additional indications.

Biogen Acquires Reata Pharmaceuticals

July 28, 2023

Biotechnology

Biogen Inc. agreed to acquire Reata Pharmaceuticals, Inc. for $172.50 per share in cash, representing an enterprise value of approximately $7.3 billion. The acquisition adds Reata's FDA-approved SKYCLARYS (omaveloxolone) for Friedreich's ataxia to Biogen's rare disease portfolio and is expected to be significantly accretive to Biogen's Non-GAAP diluted EPS beginning in 2025; the transaction was anticipated to close in Q4 2023.

Roche Acquires Good Therapeutics to Gain PD-1-regulated IL-2 Program

September 7, 2022

Biotechnology

Roche has entered into a definitive merger agreement to acquire Good Therapeutics, a Seattle-based privately held biopharmaceutical company, for an upfront $250 million plus milestone payments. The deal gives Roche rights to Good Therapeutics' conditionally active PD-1-regulated IL-2 program and an exclusive right to the platform for developing PD-1-regulated IL-2 receptor agonists; the transaction is expected to close in Q3 2022 subject to HSR clearance.

GSK to Acquire IDRx in Up-to $1.15 Billion Deal

January 15, 2025

Biotechnology

GSK has entered into an agreement to acquire IDRx, a Boston-based clinical-stage biopharmaceutical company focused on precision therapeutics for GIST. The deal includes an upfront payment of $1 billion plus a potential additional $150 million success-based regulatory milestone payment.

Sanofi to Acquire Blueprint Medicines to Expand Rare Immunology Pipeline

June 2, 2025

Pharmaceuticals

Sanofi and Blueprint Medicines entered into an agreement under which Sanofi will acquire Blueprint via a cash tender offer and subsequent merger. The deal values Blueprint at $129.00 per share in cash (approximately $9.1 billion equity value), with additional potential milestone payments tied to BLU-808 via a contingent value right.